<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05054231</url>
  </required_header>
  <id_info>
    <org_study_id>SI-CART-IPC 2019-006</org_study_id>
    <nct_id>NCT05054231</nct_id>
  </id_info>
  <brief_title>Immunological Profile for Patients Treated With CAR-T Cells</brief_title>
  <acronym>SI-CART</acronym>
  <official_title>Immunological Profile for Patients Treated With CAR-T Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the frame of Si-CART study, blood will be collected from patients treated with CAR-T&#xD;
      cells: before (at Day (D)-6 and D0 before cells injection), post infusion at D3, D5,D7, D9,&#xD;
      D11, D14, D18, D 21, Month (M) 2 and M12 post injection.&#xD;
&#xD;
      A cerebrospinal fluid sample will also be collected if a Cerebrospinal Fluid Analysis Lumbar&#xD;
      puncture is performed&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 5, 2021</start_date>
  <completion_date type="Anticipated">October 5, 2026</completion_date>
  <primary_completion_date type="Anticipated">October 5, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between serum markers and adverse events at 1 year of the CAR-T cells infusion</measure>
    <time_frame>1 year after T cells infusion</time_frame>
    <description>Serum concentration of cytokines in relation to adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CAR-T cells rate from infusion to one year after CAR-T cells infusion</measure>
    <time_frame>From CAR-T cells infusion to one year</time_frame>
    <description>Flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a relapse</measure>
    <time_frame>From CAR-T cells infusion to one year</time_frame>
    <description>Relapse rate from CAR-T cells infusion to one year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a cytokine release syndrome</measure>
    <time_frame>From CAR-T cells infusion to one year</time_frame>
    <description>Cytokine release syndrome from CAR-T cells infusion to one year</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Hematologic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Patient treated with CAR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample collection</intervention_name>
    <description>Blood samples collection: at Day (D)-6 and D0 before CAR-T cells injection, post injection at Day (D)3, D5,D7, D9, D11, D14, D18, D 21, Month 2 and Month 12 post injection.</description>
    <arm_group_label>Patient treated with CAR-T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Planned injection of CAR-T cells within the scope of marketing authorization&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  French social security affiliation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women, or women of childbearing potential (without medically acceptable&#xD;
             contraception) or breastfeeding women.&#xD;
&#xD;
          -  Patient in emergency situation, adult under legal protection (patient placed under&#xD;
             tutorship, curatorship, or judicial protection) or unable to give his consent&#xD;
&#xD;
          -  Impossibility to comply with trial medical follow-up for geographic, social or&#xD;
             psychological reasons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dominique GENRE, MD</last_name>
    <phone>+33491223778</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jihane PAKRADOUNI, Pharm PhD</last_name>
    <phone>+33491223778</phone>
    <email>pakradounij@ipc.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>GENRE Dominique, MD</last_name>
      <phone>33(0) 4 91 22 37 78</phone>
      <email>drci.up@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Claude Lemarié, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 28, 2020</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAR-T cells</keyword>
  <keyword>Immunological Profile</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

